Find the latest 10x Genomics, Inc. (TXG) stock quote, history, news and other vital information to help you with your stock trading and investing 10x Genomics (TXG) Looks Good: Stock Adds 6.2% in Session 10x Genomics (TXG) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes. Jun. 16, 2020 at 8:39 a.m.
10x Genomics' stock is owned by a number of retail and institutional investors. Top institutional investors include Paragon Advisors LLC (0.01%) and Hamilton Lane Advisors LLC (0.00%). Company insiders that own 10x Genomics stock include Associates Vi LP Venrock, Benjamin J Hindson, Bryan E Roberts, Foresite Capital Fund I, LP, Foresite Capital Management I John R Stuelpnagel and Serge. The Investor Relations website contains information about 10x Genomics's business for stockholders, potential investors, and financial analysts 10X Genomics Stock. Innovative Genomics Platform. Founded. 2012. Notable Investors. Fidelity Investments. Headquarters. Pleasanton CA, US. Total Funding. $238M. About 10X Genomics Stock. 10x Genomics is creating revolutionary DNA sequencing technology to help researchers better identify subtle variations that are overlooked by technologies that shred biological samples into tiny fragments.
10X Genomics market cap is $9 b, and annual revenue was $245.89 m in FY 2019. View 10X Genomics stock / share price, financial statements, key ratios and more at Craft 10x Genomics (TXG) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes. 10x Genomics (TXG) Looks Good: Stock Adds 6.2% in Session - June 16, 2020 - Zacks.co 10x Genomics is an American biotechnology company that designs and manufactures gene sequencing technology used in scientific research. It was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness. Customers include research centers, academic institutions, clinical research organizations and biotechnology companies.. Buy 10x Genomics Inc Class A stock (TXG). See 10x Genomics Inc Class A real time stock price, historical quotes and price charts. Stay up to date with 10x Genomics Inc Class A stock news. Invest in 10x Genomics Inc Class A stock and others with any dollar amount Analysts who follow 10X Genomics Inc on average expect it to decline -0.76% over the next twelve months.Those same analysts give the stock an average rating of Strong Buy. That average rating earns the stock an Analyst Ranking of 80, which means it ranks higher than 80 of stocks, based on data compiled by InvestorsObserver
10x Genomics Launches Next Generation Immune Profiling Product to Combat COVID-19 July 8, 2020 10x Genomics to Report Second Quarter Financial Results on August 11, 202 Class A Common Stock: DE: EUR: Sep 2019: 1KJ: DB (Deutsche Boerse AG)Yes: Class A Common Stock: DE: EUR: Sep 2019: Biography. 10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Its company offers chromium instruments.
Find the latest SEC Filings data for 10x Genomics, Inc. Class A Common Stock (TXG) at Nasdaq.com View the latest 10x Genomics Inc. (TXG.US) stock price, news, historical charts, analyst ratings and financial information from WSJ About 10x Genomics 10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company's integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x. 7 Wall Street analysts have issued ratings and price targets for 10x Genomics in the last 12 months. Their average twelve-month price target is $86.43, suggesting that the stock has a possible downside of 5.92%. The high price target for TXG is $105.00 and the low price target for TXG is $62.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of Buy TXG: Get the latest 10x Genomics stock price and detailed information including TXG news, historical charts and realtime prices
The victory in the patent dispute sent shares of 10x Genomics soaring to end the year. The stock gained 44.5% in 2019, dating back to its initial public offering (IPO) in the fall. Considering the. . (TXG) stock price, news, historical charts, analyst ratings and financial information from WSJ View today's stock price, news and analysis for 10x Genomics Inc. (TXG). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and more
10x Genomics, Inc. Class A Common Stock, also called 10x Genomics, is a life science technology company, which engages in building products to interrogate, understand and master biology. Read More Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single.